paywalled: US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology (breast/ovarian mutation)

US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology

US firm corners exclusive license for RAD51C cancer gene

Bryant Furlow

 

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C , under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.

“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University"

[Lancet Oncology News] US firm corners exclusive license for RAD51C cancer gene

[News] US firm corners exclusive license for RAD51C cancer gene:

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C, under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks."

US firm (Myriad) corners exclusive license for RAD51C (breast/ovarian)cancer gene : The Lancet Oncology

 abstract

Bryant Furlow

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C , under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.

“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University ..."

To read this article in full you will need to make a payment

Myriad Genetics Gets (Worldwide) Rights To RAD51C Gene

"...Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C."

Hereditary ovarian cancer: Beyond the usual suspects - abstract (Fanconi anemia–BRCA,PARP, RAD51C, RAD51D,BRIP1

Blogger's Note: see post Myriad Genetics  rights/RAD51C

.....With at least 16 genes implicated in hereditary ovarian cancer to date, comprehensive testing for ovarian cancer risk will require assessment of many genes........ In addition, identifying inherited mutations in a variety of FA–BRCA pathway genes may aid in identifying individuals who will selectively benefit from PARP inhibitors."

---

Highlights

► Newly identified hereditary ovarian cancer genes include RAD51C, RAD51D, and BRIP1.
► Many genes in the Fanconi anemia–BRCA pathway may increase risk of ovarian cancer.
► New genomic technologies make comprehensive genetic assessment feasible.

Gene link to cancer risk in families - protein RAD51C (news item) breast and ovarian

Note: this report is worthwhile reading especially for those who test negative for BRCA 1/2

"No significant mutations were found in RAD51C in the 620 families with breast cancer only.  However, when they looked at the breast and ovarian cancer families, things got really interesting.  In all, they were able to identify a total of 6 mutations in the 480 families that had sufficient evidence to implicate them in the breast and ovarian cancer susceptibility.  Thus, in this German study of women with unexplained familial breast and ovarian cancer, the cancer susceptibility in 1.3% of the families could be explained by heterozygous mutations in the RAD51C gene."